Complimentary access to the JTO and a 15% discount on the publication fees for the newest open-access IASLC journal, JTO CRR. Both JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO is among the top 5% of all oncology journals and the leading journal that is entirely focused on thoracic oncology.
JTO and JTO CRR feature novel research about the prevention, detection, diagnosis, and treatment of all thoracic malignancies. With an Impact Factor of 21.1, JTO is among the top 4% of all oncology journals and the leading journal that is entirely focused on thoracic oncology. It emphasizes a multidisciplinary approach and includes original research, reviews, and opinion pieces. JTO CRR, IASLC’s open-access companion title, publishes a range of manuscripts, from subset analyses of published trials to high-quality case reports. JTO CRR has an Impact Factor of 3.0 and is indexed in PubMed and Web of Science.
JTO by the Numbers
13
out of 322 in Oncology Journals
2
out of 100 in Respiratory Journals
21.1
Impact Factor (up from 20.4 in 2022)
1,704%
increase in 6 years full-text article downloads
EDITOR-IN-CHIEF, JTO ON 2023 IMPACT FACTOR
Alex A. Adjei, MD, PhD, FACP
"JTO's impact factor for 2023 has risen to 21.1, making it only the second respiratory journal (after Lancet Respiratory Medicine) with an impact factor above 20. More importantly, it is the only thoracic oncology journal with an impact factor greater than 10. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals, and we now rank 13th out of 322 oncology journals. This achievement is a testament to the exemplary work of our editorial board and our editorial office, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology."
JTO CRR By the Numbers
142
out of 322 Oncology Journals
37
out of 100 Respiratory Journals
3.0
2023 Impact Factor
EDITOR-IN-CHIEF, JTO CRR ON 2023 IMPACT FACTOR
Emily Stone, MBBS, PhD, FRACP
“The JTO CRR team is celebrating our first impact factor at 3.0, and we wish to thank everyone who made it possible – the authors, reviewers, editors, and the IASLC. We are thrilled to make such a terrific start, which truly reflects our commitment to excellence in science.”
Most-Cited Journal of Thoracic Oncology Articles in 2024
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer
Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Recent journal articles
Novel approach to proficiency testing reveals significant variations in biomarker practice leading to critical differences in lung cancer management.
Retreatment with Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response
Turtle study: A phase II study of durvalumab plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancer (LOGiK 2003)
Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial
High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial
Misleading Interpretations of the MET Gene Acronym: Over 15 Years of Confusion in Scientific Publications and a Call for Reaffirming the Original Gene Nomenclature
Combination Therapy with MET-TKI and EGFR-TKI in patients with MET-overexpressed EGFR-mutant Lung Adenocarcinoma
Cost-Effectiveness Of Adjuvant Osimertinib With And Without Chemotherapy For Surgically Resected Non-Small Cell Lung Cancer
Discover the JTO
JTO.org offers numerous ways to stay abreast of novel research and information vital to your daily oncology practice. Join the JTO reader community to:
More than 80 international experts compose the JTO Editorial Board, allowing for a quick turn-around time of 1 week to initial decision, and an average of 1.6 weeks for revisions, a fast track category, publish on acceptance (within 5 days), and promotion of select articles via social media and press releases.
JTO emphasizes a multidisciplinary approach and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. Authors can take advantage of Elsevier's Researcher Academy, Navigate your research journey with Researcher Academy—free e-learning modules on navigating your career developed by global experts.
JTO reviewers are given the privilege of getting the first look at novel research, phase III data, and potentially practice-changing concepts. Email your CV to JTO@iaslc.org.
New JTO Collections
Discover the JTO CRR
Providing a more clinical focus, the JTO CRR contains phase I thoracic oncology clinical trials and single-arm phase II trials, as well as case reports, subset analyses of a published trials, database analyses, retrospective trials, and large single-institution series.
In addition to the content discussed previously, JTO CRR also accepts region-specific clinical trials, subspecialty thoracic oncology studies, and select high-quality meeting reports.
To become a JTO CRR Reviewer email your CV to JTOCRR@iaslc.org.
Related Content
